Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
about
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
P2860
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@ast
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@en
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@nl
type
label
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@ast
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@en
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@nl
prefLabel
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@ast
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@en
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@nl
P2093
P2860
P356
P1476
Medical strategies for treatme ...... cer (CRPC) docetaxel resistant
@en
P2093
Antonella Palazzo
Daniele Alesini
Emanuela Risi
Enrico Cortesi
Giuseppe Maria Campennì
Roberto Iacovelli
P2860
P304
P356
10.4161/CBT.21188
P407
P577
2012-07-24T00:00:00Z